Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide
Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after it failed to meet the main goal of a late-stage trial, sending its shares down 10% in premarket trading.
Sage Gemini faces sexual assault allegations
TD Cowen analyst Ritu Baral maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of ...
Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...
Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the ...
SAGE Therapeutics (SAGE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas ...
Twice a year Purple Sage Pottery opens its doors for an open studio sale. Sixteen local potters will offer a variety of ...
Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...
Bank of America Securities analyst Tazeen Ahmad has reiterated their bearish stance on SAGE stock, giving a Sell rating on October 4. Tazeen ...
The Manhattan owner's inspiration comes from hospitality giants such as Four Seasons and Hilton — and, yes, WeWork.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback